140 related articles for article (PubMed ID: 10923223)
1. Cutaneous porphyria in a neonate with tyrosinaemia type 1.
Vanden Eijnden S; Blum D; Clercx A; Goyens P; De Laet C; Vamos E
Eur J Pediatr; 2000 Jul; 159(7):503-6. PubMed ID: 10923223
[TBL] [Abstract][Full Text] [Related]
2. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM
Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276
[TBL] [Abstract][Full Text] [Related]
3. Hereditary tyrosinaemia type I: from basics to progress in treatment.
Pitkänen ST; Salo MK; Heikinheimo M
Ann Med; 2000 Nov; 32(8):530-8. PubMed ID: 11127930
[TBL] [Abstract][Full Text] [Related]
4. Type 1 Tyrosinaemia.
Mannion MA; Smith A; Mayne P; Monavari AA
Ir Med J; 2016 Jun; 109(6):426. PubMed ID: 27814443
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of NTBC after liver transplantation in tyrosinemia type 1.
Kurihara K; Toyoda H; Amoano K; Inoue M; Uchida K; Sakurai H; Hayashi A; Hirayama M
Pediatr Int; 2018 Nov; 60(11):1039-1041. PubMed ID: 30375135
[No Abstract] [Full Text] [Related]
6. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation.
Joshi SN; Venugopalan P
Ann Trop Paediatr; 2004 Sep; 24(3):259-65. PubMed ID: 15479577
[TBL] [Abstract][Full Text] [Related]
7. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
Holme E; Lindstedt S
J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
[TBL] [Abstract][Full Text] [Related]
8. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
Gissen P; Preece MA; Willshaw HA; McKiernan PJ
J Inherit Metab Dis; 2003; 26(1):13-6. PubMed ID: 12872835
[TBL] [Abstract][Full Text] [Related]
9. Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC).
Sander J; Janzen N; Terhardt M; Sander S; Gökcay G; Demirkol M; Ozer I; Peter M; Das AM
Clin Chim Acta; 2011 Jan; 412(1-2):134-8. PubMed ID: 20883679
[TBL] [Abstract][Full Text] [Related]
10. From Weed Killer to Wonder Drug.
Lock EA
Adv Exp Med Biol; 2017; 959():175-185. PubMed ID: 28755195
[TBL] [Abstract][Full Text] [Related]
11. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
Crone J; Möslinger D; Bodamer OA; Schima W; Huber WD; Holme E; Stöckler Ipsiroglu S
Acta Paediatr; 2003 May; 92(5):625-8. PubMed ID: 12839296
[TBL] [Abstract][Full Text] [Related]
12. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.
Masurel-Paulet A; Poggi-Bach J; Rolland MO; Bernard O; Guffon N; Dobbelaere D; Sarles J; de Baulny HO; Touati G
J Inherit Metab Dis; 2008 Feb; 31(1):81-7. PubMed ID: 18214711
[TBL] [Abstract][Full Text] [Related]
13. Elevated plasma bile acid concentrations in two sisters with tyrosinaemia type I.
Sass JO; Skladal D
J Paediatr Child Health; 2000 Feb; 36(1):91-3. PubMed ID: 10723702
[TBL] [Abstract][Full Text] [Related]
14. Outcome of children with hereditary tyrosinaemia following newborn screening.
McKiernan PJ; Preece MA; Chakrapani A
Arch Dis Child; 2015 Aug; 100(8):738-41. PubMed ID: 25564536
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
Spiekerkoetter U; Couce ML; Das AM; de Laet C; Dionisi-Vici C; Lund AM; Schiff M; Spada M; Sparve E; Szamosi J; Vara R; Rudebeck M
Lancet Diabetes Endocrinol; 2021 Jul; 9(7):427-435. PubMed ID: 34023005
[TBL] [Abstract][Full Text] [Related]
16. Nitisinone in the treatment of hereditary tyrosinaemia type 1.
McKiernan PJ
Drugs; 2006; 66(6):743-50. PubMed ID: 16706549
[TBL] [Abstract][Full Text] [Related]
17. Neonatal screening for hereditary tyrosinaemia: are we there yet?
Hadžić N; Vara R
Arch Dis Child; 2015 Aug; 100(8):720-1. PubMed ID: 25957320
[No Abstract] [Full Text] [Related]
18. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.
Lock EA; Ellis MK; Gaskin P; Robinson M; Auton TR; Provan WM; Smith LL; Prisbylla MP; Mutter LC; Lee DL
J Inherit Metab Dis; 1998 Aug; 21(5):498-506. PubMed ID: 9728330
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.
De Laet C; Munoz VT; Jaeken J; François B; Carton D; Sokal EM; Dan B; Goyens PJ
Dev Med Child Neurol; 2011 Oct; 53(10):962-4. PubMed ID: 21745202
[No Abstract] [Full Text] [Related]
20. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
